Press Releases June 12, 2026 08:00 AM

Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2026 MedTech Innovation Spotlight

Inspire Medical Systems to Present at Wells Fargo 2026 MedTech Innovation Spotlight

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
INSP

Inspire Medical Systems, a US-based medical device company specializing in innovative treatments for obstructive sleep apnea, announced its management team's participation in the Wells Fargo 2026 MedTech Innovation Spotlight scheduled for June 26, 2026. The company will webcast its presentation, showcasing its proprietary Inspire therapy, an FDA and EU approved neurostimulation treatment for moderate to severe sleep apnea.

Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2026 MedTech Innovation Spotlight
INSP
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Inspire Medical Systems focuses on minimally invasive, innovative solutions for obstructive sleep apnea, a significant health issue.
  • The company's therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology for moderate to severe obstructive sleep apnea.
  • Participation in the Wells Fargo MedTech Innovation Spotlight increases visibility among investors and industry stakeholders.

MINNEAPOLIS, June 12, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will participate in the Wells Fargo 2026 MedTech Innovation Spotlight on Friday, June 26, 2026.

Inspire is scheduled to speak at 10:00 a.m. Eastern Time. The presentation will be accessible via a live webcast here.

A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire’s Investor website at https://investors.inspiresleep.com.

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443


Risks

  • Market adoption of Inspire's therapy can be affected by regulatory changes or competition from alternative treatments, impacting medtech sector.
  • The company's growth is linked to continuing approvals and payer reimbursement policies, which can be uncertain.
  • Dependence on successful commercialization strategies and maintaining technological leadership in a competitive medical device market.

More from Press Releases

America’s Car-Mart, Inc. Announces Agreement with Lenders to Support Ongoing Strategic Review Process Jun 19, 2026 Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 9, 2026 Jun 19, 2026 Weatherford Announces Second-Quarter 2026 Conference Call Jun 19, 2026 Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders Jun 19, 2026 SPX Technologies Announces Leadership Transition in D&M Segment Jun 19, 2026